Forecasting pharmacokinetics (PK) for individual patients is a fundamental problem in clinical pharmacology. One key challenge is that PK models constructed using data from one dosing regimen must predict PK data for different dosing regimen(s). We propose a deep learning approach based on neural ordinary differential equations (neural-ODE) and tested its generalizability against a variety of alternative models. Specifically, we used the PK data from two different treatment regimens of trastuzumab emtansine. The models performed similarly when the training and the test sets come from the same dosing regimen. However, for predicting a new treatment regimen, the neural-ODE model showed substantially better performance. To date, neural-ODE is the most accurate PK model in predicting untested treatment regimens. This study represents the first time neural-ODE has been applied to PK modeling and the results suggest it is a widely applicable algorithm with the potential to impact future studies.
Recent breakthroughs in artificial intelligence (AI) and machine learning (ML) have ushered in a new era of possibilities across various scientific domains. One area where these advancements hold significant promise is model‐informed drug discovery and development (MID3). To foster a wider adoption and acceptance of these advanced algorithms, the Innovation and Quality (IQ) Consortium initiated the AI/ML working group in 2021 with the aim of promoting their acceptance among the broader scientific community as well as by regulatory agencies. By drawing insights from workshops organized by the working group and attended by key stakeholders across the biopharma industry, academia, and regulatory agencies, this white paper provides a perspective from the IQ Consortium. The range of applications covered in this white paper encompass the following thematic topics: (i) AI/ML‐enabled Analytics for Pharmacometrics and Quantitative Systems Pharmacology (QSP) Workflows; (ii) Explainable Artificial Intelligence and its Applications in Disease Progression Modeling; (iii) Natural Language Processing (NLP) in Quantitative Pharmacology Modeling; and (iv) AI/ML Utilization in Drug Discovery. Additionally, the paper offers a set of best practices to ensure an effective and responsible use of AI, including considering the context of use, explainability and generalizability of models, and having human‐in‐the‐loop. We believe that embracing the transformative power of AI in quantitative modeling while adopting a set of good practices can unlock new opportunities for innovation, increase efficiency, and ultimately bring benefits to patients.
1 December 2021 in JCO Clinical Cancer Informatics
PURPOSE: The application of Cox proportional hazards (CoxPH) models to survival data and the derivation of hazard ratio (HR) are well established. Although nonlinear, tree-based machine learning (ML) models have been developed and applied to the survival analysis, no methodology exists for computing HRs associated with explanatory variables from such models. We describe a novel way to compute HRs from tree-based ML models using the SHapley Additive exPlanation values, which is a locally accurate and consistent methodology to quantify explanatory variables’ contribution to predictions. METHODS: We used three sets of publicly available survival data consisting of patients with colon, breast, or pan cancer and compared the performance of CoxPH with the state-of-the-art ML model, XGBoost. To compute the HR for explanatory variables from the XGBoost model, the SHapley Additive exPlanation values were exponentiated and the ratio of the means over the two subgroups was calculated. The CI was computed via bootstrapping the training data and generating the ML model 1,000 times. Across the three data sets, we systematically compared HRs for all explanatory variables. Open-source libraries in Python and R were used in the analyses. RESULTS: For the colon and breast cancer data sets, the performance of CoxPH and XGBoost was comparable, and we showed good consistency in the computed HRs. In the pan-cancer data set, we showed agreement in most variables but also an opposite finding in two of the explanatory variables between the CoxPH and XGBoost result. Subsequent Kaplan-Meier plots supported the finding of the XGBoost model. CONCLUSION: Enabling the derivation of HR from ML models can help to improve the identification of risk factors from complex survival data sets and to enhance the prediction of clinical trial outcomes.
10 April 2025 in Clinical and Translational Science
Large language models (LLMs) have emerged as powerful tools in many fields, including clinical pharmacology and translational medicine. This paper aims to provide a comprehensive primer on the applications of LLMs to these disciplines. We will explore the fundamental concepts of LLMs, their potential applications in drug discovery and development processes ranging from facilitating target identification to aiding preclinical research and clinical trial analysis, and practical use cases such as assisting with medical writing and accelerating analytical workflows in quantitative clinical pharmacology. By the end of this paper, clinical pharmacologists and translational scientists will have a clearer understanding of how to leverage LLMs to enhance their research and development efforts.